Search

everythinglearnresearchcommunity

for

Search:↓

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

A 39-year-old user has been using topical 0.3% finasteride with 6% minoxidil for almost 7 months without seeing significant improvement in hair regrowth. They are considering switching to a gel with higher minoxidil concentration, adding retinoic acid, or trying topical dutasteride, while others suggest returning to 5% minoxidil foam, adding oral finasteride, or exploring microneedling and lifestyle changes.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

The user quit oral finasteride over a year ago, experienced improvements in brain fog and erectile dysfunction after quitting smoking and porn, and plans to try dutasteride. Another user shared their experience with finasteride, mentioning panic attacks and anxiety, and managed symptoms through lifestyle changes like meditation and exercise.

The user experienced significant hair regrowth using a topical treatment of Minoxidil and Finasteride, despite some brain fog as a side effect. They recommend starting treatment early and suggest topical options to minimize side effects compared to oral treatments.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The user experienced hair regrowth after three months of using 1mg finasteride and inconsistent minoxidil. They plan to be more consistent with minoxidil application to improve results further.

A 24-year-old male shared his 5.5-year progress using minoxidil and nearly 5 years on finasteride/dutasteride for hair loss, reporting no side effects and successful results. He uses 0.5 mg dutasteride daily, oral minoxidil 2.5 mg daily, and topical minoxidil daily, with costs around $4 monthly.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Creating custom topical treatments for hair loss using minoxidil, finasteride, and RU58841. It includes recipes and instructions for home preparation, focusing on cost savings and customization.

Nizoral, a ketoconazole shampoo, can cause scalp dryness and hair shedding if overused. Users discuss alternatives like Selsun Blue, finasteride, and dutasteride for managing hair loss and seborrheic dermatitis.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

A 47-year-old male experienced significant hair regrowth over six months using 1mg oral finasteride, 5mg oral minoxidil, and 1ml 5% topical minoxidil, along with weekly derm stamping. He reported no major side effects, improved prostate health, and increased vascularity, with hair texture changes and minor nasal congestion.

The user is dealing with early hair loss and is using a serum with Redensyl, multivitamins, and plans to add minoxidil. They seek advice on maintaining a positive mindset and improving hair health through lifestyle changes.

The user has been using dutasteride twice a week for 8 months and oral minoxidil for 3 months but is experiencing increased hair thinning. Many recommend taking dutasteride daily for improved results.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The conversation is about treating hair loss without finasteride or dutasteride due to sensitivity causing gynecomastia. The user plans to use pyrilutamide, RU58841, and oral Minoxidil instead.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

The user has been using oral minoxidil (5mg), finasteride (1mg), and biotin for 4 months with minimal progress in hair regrowth. Other users suggest patience, considering alternative treatments, and note that biotin may not significantly contribute unless there's a deficiency.

The user shared progress pictures showing hair improvement over three months using a treatment of 5% minoxidil and 0.1% finasteride solution, along with occasional biotin and multivitamins. Another user discussed their regimen of topical minoxidil, oral minoxidil, finasteride, iron supplements, and dutasteride, seeking advice on application routines.

The conversation is about a user experiencing hair shedding after starting a treatment with oral minoxidil, topical minoxidil, and finasteride. Other users reassure that shedding is normal and part of the process, suggesting it will lead to stronger hair growth.

The user has been using Dutasteride and topical Minoxidil for hair loss, considering switching to oral Minoxidil and increasing Dutasteride dosage. They are seeking advice on whether to change their current regimen or continue, with some users suggesting oral Minoxidil and others cautioning about potential side effects.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.